EUROMALVAC
European
Malaria
Vaccine
Consortium
EM
VC
xx You are here: Home Page -> Members ->Profile: Arnot
|
EUROMALVAC |
European | EM |
|
|
|||
xx You are here: Home Page -> Members ->Profile: Arnot | |||
|
|
|||
|
|
|
Dr David Arnot
|
| |
|
The EUROMALVAC consortium is a cluster comprising 12 partners in 9 separate institutions whose objective is to provide a development pipeline for malaria vaccine candidates. The coordinating institution is the University of Edinburgh, which is represented by Dr David Arnot. Dr Arnot coordinates the scientific, administrative and financial activities of the Consortium and liaises directly with Dr Andreas Holtel, the responsible Scientific Officer at the European Commission. Edinburgh University, the Coordinating Partner, is guided by the Management Board of the Consortium (which consists of one voting member representing each of the partner Institutions). Florance Kennedy, the Consortium's Project Administrator, assists Dr Arnot. In addition to acting as Coordinator of the Consortium Dr David Arnot is also a scientific partner and member of the PfEMP-1 vaccine development group. His laboratory is involved in research on parasite cytoadhesion and parasite ligand characterisation and structural analysis. He also contributes results and samples from well characterised collections of sera and parasite isolates from field research work. Part of the Consortium's work is on the immuno-epidemiological analysis of correlates of immunity to malaria and on the search for commonly recognised epitopes of the PfEMP-1 molecule. Other partners involved in this work are Drs Thor Theander, Jana McBride, Mo Klinkert, David Conway and Prof Mats Wahlgren. David Arnot has 23 years experience in the molecular biology of parasitic protozoa, particularly, malaria parasites. He is currently a Wellcome Trust University Fellow in the Institute of Cell, Animal and Population Biology at the University of Edinburgh. Since 1989 he has worked at Edinburgh University on genetic diversity in Plasmodium falciparum, on infection and immunity to malaria in Africa and on the molecular cell biology of Plasmodium falciparum. While a member of Prof Ruth Nussenzweig's New York University sporozoite vaccine development group between 1983-1989, he was the first person to clone and characterise the CS genes of P. vivax and other simian and rodent sporozoite genes. Currently he is also the Coordinator of the INCO-DC Project "Immunity to Malaria in African villages" a collaborative programme of research on immune responses to genetically diverse malaria infections with the Universities of Khartoum, Ghana and Copenhagen. | ||||
Home | Introduction | Coordination | Members | Objectives | Workplan | Links
Please send your comments etc. regarding this site to